MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co EBITDA per Employee

The EBITDA per Employee of MicroTech Medical (Hangzhou) Co (2235.HK) as of Nov 2, 2026 is 77,691.10 CNY. In the previous year, EBITDA per Employee was -83,309.26 CNY — a change of -193.26% (higher).

EBITDA per Employee

77,691.10CNY

YoY

-193.26%

Last updated:

EBITDA per Employee of MicroTech Medical (Hangzhou) Co is 2025 77,691.10 CNY. EBITDA per Employee of MicroTech Medical (Hangzhou) Co was 2024 -83,309.26 CNY. It decreases by -193.26% higher compared to the previous year.

The MicroTech Medical (Hangzhou) Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-147,203.60 CNY
Jan 1, 2020
-258,784.75 CNY
Jan 1, 2021
-106,301.93 CNY
Jan 1, 2022
-46,017.42 CNY
Jan 1, 2023
-170,969.07 CNY
Jan 1, 2024
-83,309.26 CNY
Jan 1, 2025
77,691.10 CNY
The MicroTech Medical (Hangzhou) Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
77,691.10CNY-193.26%
-83,309.26CNY-51.27%
-170,969.07CNY+271.53%
-46,017.42CNY-56.71%
-106,301.93CNY-58.92%
-258,784.75CNY+75.80%
-147,203.60CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

EBITDA per Employee of MicroTech Medical (Hangzhou) Co is 77,691.10 CNY in 2025.

EBITDA per Employee of MicroTech Medical (Hangzhou) Co changed from -83,309.26 CNY to 77,691.10 CNY, representing a -193.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's MicroTech Medical (Hangzhou) Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co